A case study to evaluate the efficacy and safety of Collashot C2 Plus inosteoarthritis patients - NI

Innovcare LifeSciences Pvt Ltd0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•1. Have osteoarthritis (OA) of the knee joint based on American College of Rheumatology (ACR)
•criteria and confirmed with X-rays and ACR functional class of III and with grade 3 or 4 as per
•Kellgren and Lawrence classification system.
•2. Have been on stable dose of prescription Nonsteroidal Anti- Inflammatory Drugs (NSAIDS), or
•acetaminophen of at least 2000 mg per day for at least 20 days in the past month.
•3. Pain defined by a level of greater than or equal to 30 mm on a 100 mm Visual Analogue Scale
•4. Patient should have not participated in any other clinical trial during the past 3 months.
•5. Participants, who are willing to give written, signed and dated informed consent to participate in

•1. Arthritis of the knee from other causes
•2. Uncontrolled hypertension or diabetes
•3. Have OA pain that requires treatment with potent opioids, systemic corticosteroids, intra-
•articular injections, duloxetine, or venlafaxine
•4. Moderate to severe renal impairment
•5. Pregnant or lactating
•6. Received any other investigational medicine within 7 days prior to screening which can
•interfere with investigational product activity
•7. Suffering from any illness which will interfere with present study as decided by clinical
•investigator
•8. History of hypersensitivity to any of the test products.
•9. Any condition decided as unfit for study by clinical investigator

发起方

Innovcare LifeSciences Pvt Ltd